- Home
- GMAB vs ITT Comparison
GMAB vs ITT Comparison
Compare GMAB & ITT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GMAB
- ITT
- Stock Information
- Founded
- GMAB 1999
- ITT 1920
- Country
- GMAB Denmark
- ITT United States
- Employees
- GMAB N/A
- ITT N/A
- Industry
- GMAB Biotechnology: Pharmaceutical Preparations
- ITT Fluid Controls
- Sector
- GMAB Health Care
- ITT Industrials
- Exchange
- GMAB Nasdaq
- ITT Nasdaq
- Market Cap
- GMAB 15.0B
- ITT 13.0B
- IPO Year
- GMAB N/A
- ITT N/A
- Fundamental
- Price
- GMAB $20.31
- ITT $143.70
- Analyst Decision
- GMAB Buy
- ITT Strong Buy
- Analyst Count
- GMAB 8
- ITT 9
- Target Price
- GMAB $43.00
- ITT $166.88
- AVG Volume (30 Days)
- GMAB 1.2M
- ITT 338.0K
- Earning Date
- GMAB 02-12-2025
- ITT 02-06-2025
- Dividend Yield
- GMAB N/A
- ITT 0.89%
- EPS Growth
- GMAB 14.35
- ITT 11.49
- EPS
- GMAB 10.80
- ITT 5.85
- Revenue
- GMAB $2,967,926,227.00
- ITT $3,530,800,000.00
- Revenue This Year
- GMAB $30.31
- ITT $11.79
- Revenue Next Year
- GMAB $16.49
- ITT $7.49
- P/E Ratio
- GMAB $18.44
- ITT $24.52
- Revenue Growth
- GMAB 17.75
- ITT 9.36
- 52 Week Low
- GMAB $19.85
- ITT $113.70
- 52 Week High
- GMAB $32.88
- ITT $161.13
- Technical
- Relative Strength Index (RSI)
- GMAB 36.70
- ITT 33.70
- Support Level
- GMAB $19.99
- ITT $142.20
- Resistance Level
- GMAB $21.03
- ITT $156.08
- Average True Range (ATR)
- GMAB 0.38
- ITT 3.49
- MACD
- GMAB -0.07
- ITT -1.69
- Stochastic Oscillator
- GMAB 18.55
- ITT 17.82
About GMAB Genmab A/S ADS
Genmab AS is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
About ITT ITT Inc.
ITT Inc is a diversified manufacturer of engineered critical components and customized technology solutions predominantly for the transportation, industrial and energy markets. The company's products include, brake pads, shock absorbers, pumps, valves, connectors, switches and others. Its operating segments are; Motion Technologies (MT), Industrial Process (IP), and Connect & Control Technologies (CCT). The majority of the revenue is generated from the Motion Technologies segment which is a manufacturer of brake pads, shims, shock absorbers, energy absorption components and sealing technologies. Geographically, the company generates majority of the revenue from North America, and also has its presence in South America, Europe, Asia, Middle East and Africa.